Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Insulin aspart→

Insulin aspart Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
116094-23-6
PubChem CID
16132418
Molecular formula
C256H387N65O79S6
Molecular weight
5832 g/mol
Drug class
Insulin Analog
Mechanism of action
The primary activity of insulin, including NOVOLOG is the regulation of glucose metabolism.

Sources: FDA product labels (openFDA) · FDA product information

Identification source: PubChem record (CID 16132418). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Insulin aspart Environmental Risk Assessment (ERA) (the Insulin aspart ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.